TrialClinical pharmacology and therapeutics2021

Lorlatinib Exposure-Response Analyses for Safety and Efficacy in a Phase I/II Trial to Support Benefit-Risk Assessment in Non-Small Cell Lung Cancer.

Joseph Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.